Updates in the Management of Small Cell Lung Cancer

Presented by:
Apar Kishor Ganti
Search for other papers by Apar Kishor Ganti in
Current site
Google Scholar
PubMed Close
 MD, MS
Volume/Issue:
Volume 22: Issue Supplement
Online Publication Date:
31 May 2024
DOI:
https://doi.org/10.6004/jnccn.2024.5021
Restricted access

The standard treatment for limited-stage small cell lung cancer (SCLC) is concurrent chemoradiation, with a small subset of patients that could potentially benefit from surgery. For extensive-stage SCLC, the current standard of care is chemoimmunotherapy with a PD-1/PD-L1 inhibitor. The role of prophylactic cranial irradiation in SCLC is currently under debate, and is being investigated in the ongoing MAVERICK trial. Despite high initial response rates to chemoradiotherapy, relapse is common, and outcomes for these patients remain poor. However, recent advances in understanding the molecular biology of SCLC have led to the identification of potential new targets for treatment, including the combination of temozolomide with PARP inhibitors and DLL3-targeted bispecific T-cell engager therapy, both of which have shown activity in early studies.

Disclosures: Dr. Ganti has disclosed receiving grant/research support from Apexigen, Iovance Pharmaceuticals, Merck & Co., Inc., Mirati Therapeutics, Inc., and Nektar Therapeutics; serving as a consultant for AstraZeneca Pharmaceuticals LP, Bayer HealthCare, Cardinal Health, Jazz Pharmaceuticals, Sanofi Genzyme, and Regeneron Pharmaceuticals; serving as a scientific advisor for Flagship Biosciences; and receiving honoraria from Y-mAbs Therapeutics.

Correspondence: Apar Kishor Ganti, MD, MS, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198. Email: aganti@unmc.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Büttner R, Longshore JW, López-Ríos F, et al. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open 2019;4:e000442.

  • 2.

    Ou SHI, Zell JA. The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM edition. J Thorac Oncol 2009;4:300–310.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282–291.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Turrisi AT III, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265–271.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Bogart J, Wang X, Masters G, et al. High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)/RTOG 0538. J Clin Oncol 2023;41:2394–2402.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018;379:2220–2229.

  • 7.

    Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019;394:1929–1939.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Landre T, Chouahnia K, Des Guetz G, et al. First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis. Ther Adv Med Oncol 2020;12:1758835920977137.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Vinés EF, Le Péchoux C, Arriagada R. Prophylactic cranial irradiation in small cell lung cancer. Semin Oncol 2003;30:38–46.

  • 10.

    Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357:664–672.

  • 11.

    Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2017;18:663–671.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    O’Brien MER, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441–5447.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:2086–2092.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020;21:645–654.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Iwasaki Y, Nagata K, Nakanishi M, et al. Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer. Chest 2005;128:2268–2273.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Goldman JW, Cummings AL, Mendenhall MA, et al. Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC). J Clin Oncol 2022;40(Suppl):Abstract 8517.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Farago AF, Yeap BY, Stanzione M, et al. Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer Discov 2019;9:1372–1387.

  • 18.

    Pietanza MC, Waqar SN, Krug LM, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol 2018;36:2386–2394.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med 2023;389:2063–2075.

  • 20.

    Paz-Ares L, Spigel DR, Chen Y, et al. RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer. Cancer 2022;128:1801–1811.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Cheng Y, Wang Q, Li K, et al. Third-line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: a post hoc analysis of ALTER1202, a randomized, double-blind phase 2 study. Cancer Innov 2023;2:181–190.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2024 by the National Comprehensive Cancer Network 2024
Article Category:
Abstract
Print Publication Date:
01 May 2024
Online Publication Date:
31 May 2024

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 926 926 67
PDF Downloads 450 450 19
EPUB Downloads 0 0 0